Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 3Lung Neoplasms 2Urinary Bladder Neoplasms 1Sarcoma 1Ovarian Neoplasms 1Lymphoma 1Leukemia, Myeloid, Acute 1Fallopian Tube Neoplasms 1Carcinoma, Ovarian Epithelial 1Carcinoma, Hepatocellular 1Adenocarcinoma 1

Interventions

Sorafenib 26Nivolumab 21pembrolizumab 15Bevacizumab 14lenvatinib 12atezolizumab 9Cyclophosphamide 9Ipilimumab 8durvalumab 6camrelizumab 5apatinib 5Specimen Handling 5Radiosurgery 5tislelizumab 4fludarabine 4Immunotherapy, Adoptive 4Fluorouracil 4Doxorubicin 4tremelimumab 3toripalimab 3sintilimab 3regorafenib 3cabozantinib 3X-Rays 3Magnetic Resonance Spectroscopy 3Injections 3Everolimus 3Ethiodized Oil 3Erlotinib Hydrochloride 3tepotinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Carcinoma, Hepatocellular × belinostat × Clear all
NCT00321594 2017-11-06

Belinostat in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery

National Cancer Institute (NCI)

Phase 1/2 Completed
54 enrolled 8 charts
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡